Driehaus Capital Management 13F: Cuts DFTX Stake by $15M

Driehaus Capital Management Trims Definium Therapeutics Stake

Driehaus Capital Management lowered its exposure to Definium Therapeutics, Inc. DFTX during the period, according to a recent Form 13F filing with the Securities and Exchange Commission. The fund reduced its position by 9.6%, or 625,313 shares, leaving it with 5,911,889 shares. The remaining stake carried a reported value of $146,319,252.75 at the close of the reporting window.

Definium Therapeutics Stock Trading Levels

Shares of Definium Therapeutics traded around $24.75 as the broader market digested recent portfolio shifts. The biotechnology company carries a 50-day moving average of $42.28 and a 200-day moving average of $26.27, with a 52-week trading range spanning from $9.35 to $49.70.

Insider Buying and Selling at Definium Therapeutics, Inc.

Company leadership engaged in notable share dispositions on June 25, 2026. Chief Financial Officer Brandi Roberts sold 3,013 shares at an average price of $45.03 for a total of $135,675.39 under a planned trading program. Chief Commercial Officer Matthew Wiley disposed of 2,867 shares at the same price, totaling $129,101.01. Chief Legal Officer Mark Sullivan offloaded 13,008 shares worth $585,750.24, while Chief Medical Officer Daniel Karlin sold 10,035 shares for $451,876.05.

Analysts Set New Price Targets

Wall Street firms maintain an active view on the clinical-stage biopharmaceutical company. On October 9, 2026, JP Morgan initiated coverage with an overweight rating and an $84.00 price target. Earlier, Canaccord Genuity maintained a buy rating on September 15, 2026, raising its target to $78.00 from $64.00. Baird also maintained an outperform rating on September 15, 2026, lifting its target to $79.00 from $75.00. Additional updates came from HC Wainwright & Co., Needham, RBC Capital, B of A Securities, and Maxim Group. Overall, the stock holds a consensus recommendation of strong buy from 17 analysts, with a mean price target of $71.65.

Definium Therapeutics Business Focus

Definium Therapeutics develops novel product candidates for brain health disorders. Its lead candidate, DT120, targets generalized anxiety disorder and major depressive disorder in phase 3 trials, while DT402 is evaluated in phase 2a clinical trials for autism spectrum disorder.

Outlook and Reporting Context

Investors are tracking the next scheduled earnings report from Definium Therapeutics on November 5, 2026, for further clinical trial updates. Because 13F filings are historical snapshots that look backward at a prior quarter, they do not necessarily reflect current portfolio weightings or active trading strategies.